Patents by Inventor Tyrel T. SMITH

Tyrel T. SMITH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240239914
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Application
    Filed: October 20, 2023
    Publication date: July 18, 2024
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
  • Publication number: 20240101696
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: March 28, 2024
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Peter Probst, Tyrel T. Smith, Mark E. Branum, Randi M. Simmons
  • Patent number: 11827715
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: November 28, 2023
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
  • Publication number: 20230181732
    Abstract: Provided herein are uses of antibodies that bind to CD163 expressed on a human myeloid cell in combination with checkpoint inhibitors. Among other things, these CD163 antibodies can be used with checkpoint inhibitors in methods of treatment of humans, such as methods of treating a cancer or methods of relieving T cell suppression.
    Type: Application
    Filed: September 2, 2022
    Publication date: June 15, 2023
    Inventors: Siddarth Chandrasekaran, Tyrel T. Smith, Kamal D. Puri, Randi M. Simmons, Peter Probst, Robert J. Lechleider
  • Patent number: 11634501
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: April 25, 2023
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Peter Probst, Tyrel T. Smith, Mark E. Branum, Randi M. Simmons
  • Publication number: 20220289861
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 15, 2022
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Peter Probst, Tyrel T. Smith, Mark E. Branum, Randi M. Simmons
  • Publication number: 20210253733
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Application
    Filed: April 22, 2021
    Publication date: August 19, 2021
    Inventors: Kamal D. PURI, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
  • Patent number: 11034770
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: June 15, 2021
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
  • Publication number: 20210047424
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Application
    Filed: July 22, 2020
    Publication date: February 18, 2021
    Inventors: Kamal D. PURI, Siddarth CHANDRASEKARAN, Melissa L. CONERLY, Randi M. SIMMONS, Tyrel T. SMITH, Mark E. BRANUM, Peter PROBST